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Abstract 
Familial Mediterranean Fever (FMF) is a condition 
characterized by recurrent febrile poly-serositis. Typical 
presentations of the disease include episodes of fever, 
abdominal pain and joint pains. Chest pain is a less 
common presentation. We report a case of FMF which 
presented with a large pericardial effusion and bilateral 
pleural effusions in a lady who had no positive family 
history and negative genetic testing.  
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A thirty-four year old lady was admitted to the 
emergency department with a three day history of 
central pleuritic chest pain associated with dyspnoea and 
low grade fever (37.6°C). The patient had been in good 
health prior to this admission but complained of similar 
symptoms over the previous four years. These symptoms 
used to last around three to five days and occurred 
approximately three times a year. Investigations were 
being carried out to identify the cause of these symptoms 
prior to her admission. A computed tomography (CT) 
scan of the thorax revealed small bilateral pleural 
effusions. Pleurocentesis was performed; however 
analysis of the pleural fluid was equivocal. In view of 
the inconclusive result, the patient underwent an open 
lung and pleural biopsy which revealed normal lung 
parenchyma and a pleural plaque, respectively. 
On this occasion, the patient’s chest pain and 
dyspnoea were more severe than usual and hence 
necessitated medical admission. Physical examination 
revealed a distressed patient running a temperature of 
37.6°C, with a blood pressure of 112/84mmHg. The 
patient was tachycardic at 130 beats per minute and 
tachypneoic at 22 breaths per minute. On auscultation of 
the chest, there was reduced air entry at the lung bases. 
Heart sounds were reduced in intensity. The rest of the 
examination was unremarkable.  
Peripheral blood investigations revealed a 
leukocytosis of 18.98x109/L (normal values: 4.3-
11.4x109/L) with a neutrophil shift.  Erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP) 
were both elevated at 75mm 1st hour (normal values: 10-
14mm 1st hour) and 228 (normal values: 0-10mg/L) 
respectively. Serum creatinine and electrolytes were 
normal.  Peripheral blood cultures, TORCH, Epstein-
Barr Antigen PCR, Cytomegalovirus Antigen PCR, 
Mycoplasma IgM Antibody and an auto-immune screen 
were eventually all negative.  
An echocardiogram revealed a large pericardial 
effusion with no signs of cardiac tamponade or inferior 
vena cava collapse. This was also confirmed on a CT 
scan of the thorax, abdomen and pelvis (figure 1). Other 
findings on CT were an enhancing pericardium 
suggestive of inflammation, bilateral small pleural 
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effusions and minimal ascites. These findings were in 
keeping with the presence of poly-serositis. 
 
Figure 1: CT thorax showing the large pericardial 














Pending blood culture and auto-immune screen 
results, empirical treatment with intra-venous 
piperacillin-tazobactam was commenced. This antibiotic 
therapy failed to improve the patient’s symptoms and the 
inflammatory markers remained elevated.  In view of 
these intermittent, recurrent, self-resolving episodes of 
febrile pleuritis and pericarditis, a working diagnosis of 
Familial Mediterranean Fever (FMF) was put forward. 
Genetic testing for the condition was done.   
The antibiotics were stopped and colchicine was 
prescribed at 1mg daily. There was an immediate good 
response to colchicine therapy, and this continued to 
favour a diagnosis of FMF. In view of the large 
pericardial effusion, the patient was given a single intra-
venous dose of methylprednisolone to hasten its 
resolution. Daily echocardiograms showed a reduction in 
the pericardial effusion to a size of 8mm following the 
initiation of colchicine therapy. The patient was 
completely asymptomatic after seven days when she was 
discharged on colchicine 1mg daily. A follow up 
echocardiogram two weeks after discharge confirmed 
that the pericardial effusion did not re-accumulate. The 




Familial Mediterranean Fever (FMF) is a recurrent 
febrile poly-serositis inherited in an autosomal recessive 
manner, affecting mostly individuals of Mediterranean 
descent. FMF is characterized by brief recurrent, self-
limiting episodes of fever, peritonitis, pleuritis, arthritis 
and myalgia. The most frequent presenting 
manifestations include abdominal pain (90%), articular 
involvement (75%) and chest pain due to pleuritis or 
pericarditis (30-40%).1 
Pericardial involvement rates in FMF are variable 
with different studies giving incidence rates of 0.7%,2 
1.4%,3 and 27%.4 These studies have all concluded that 
pericardial involvement is a manifestation of FMF. The 
low incidence rates may be due to under-diagnosis 
whereas the higher rates can be due to the various 
methods used to define and detect pericarditis and 
pericardial effusion;5-6 hence explaining the substantial 
variability in incidence.       
This case describes a large pericardial effusion and 
bilateral pleural effusions as the major presenting 
features of FMF without any joint or abdominal 
involvement. This case is also quite unusual since the 
condition typically presents in childhood and rarely 
occurs after the age of thirty.7 In this case, the lack of a 
positive family history for FMF made the diagnosis of 
FMF more challenging. However, the word ‘familial’ in 
FMF is a misnomer since only 50% of patients with 
FMF have a positive family history.7-9 Thus; a negative 
family history does not exclude a diagnosis of FMF.   
This case highlights the fact that FMF requires a 
high index of clinical suspicion as early recognition may 
be clinically difficult in view of its non-specific 
presentation. In order to help clinicians in differentiating 
FMF from other periodic febrile illnesses, the Tel-
Hashomer Revisited Criteria can be used for the 
diagnosis of FMF. These criteria are divided into three 
major and three minor criteria as demonstrated in table 
1. A ‘definitive’ diagnosis of FMF requires the presence 
of two major criteria or one major and two minor 
criteria. The diagnosis is considered as ‘probable’ if only 
one major and one minor criteria are present. 
 
Table 1: Tel-Hashomer Revisited Criteria for the 
diagnosis of FMF 
 
From the results shown in table 1, this patient had 
satisfied two major and one minor criteria suggesting a 
‘definitive’ diagnosis of FMF. The Tel-Hashomer 






Present or Absent 
Recurrent febrile episodes 
with serositis or synovitis 
Present 
Amyloid A amyloidosis 
without a predisposing cause 
Absent 




Patient’s Case:  
Present or Absent 
Recurrent febrile episodes Present 
Erysipelas-like erythema Absent 
FMF in a 1
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Revisited Criteria can be used as a diagnostic adjunct 
given the difficulty of diagnosing FMF. A study by 
Livneh A. et al, concluded that the new set of Tel-
Hashomer Criteria were highly sensitive (>95%) and 
specific (>97%) and were reliable in diagnosing and 
distinguishing FMF from other periodic illnesses.11  
The gene responsible for FMF is the MEditerranean 
FeVer gene (MEFV) located on chromosome 16. The 
most common mutations are found in exon 2 and 10 of 
the gene. This patient had no mutations identified in 
exon 2 and 10 of the MEFV gene. Despite the negative 
genetic test, one must note that genetic testing only has a 
70-80% positive predictive value and the diagnosis of 
FMF remains clinical.1, 12 This is of marked importance 
in the Maltese isles, as no data exists regarding the 
frequency of the various mutations involved in FMF. 
This means that FMF is a clinical diagnosis and genetic 
testing may help confirm the diagnosis but not exclude 
it. Hence, in such situations the Tel-Hashomer Revisited 
Criteria are extremely valuable.   
Making an early diagnosis of FMF is of utmost 
benefit to the patient for two main reasons: 
1. The avoidance of many unnecessary investigations 
and possible surgical interventions.1 
2. Early treatment with colchicine. Colchicine is a 
tricyclic alkaloid that diminishes the number of 
FMF attacks,10 and hence prevents the occurrence 
of Amyloid A amyloidosis and eventually renal 
failure.1, 13-14 Assessment of renal amyloidosis is 
done via regular urinalysis to check for proteinuria. 
If proteinuria is detected, more definitive renal 
studies are required to assess the degree of renal 
amyloid deposition.15 
Colchicine is the mainstay of treatment in FMF.13 
However in colchicine resistant cases of FMF other 
agents have been put forward including corticosteroids, 
non-biological and biological DMARDs, interferon-
alpha16, anti-TNF agents17 and interleukin-1 receptor 
antagonists18-20. These immunosuppressive agents may 
be beneficial in an acute inflammatory episode of FMF 
but their role in FMF prophylaxis and prevention of 
amyloidosis is unclear.17 
Despite the treatment currently available for FMF 
some patients still have regular flare-ups. This 
emphasizes the importance of continuous research for 
further effective FMF treatment. There is ongoing 
research focussing on colchicine analogues which have a 
greater therapeutic window and are less toxic than 
colchicine.21 
In conclusion, pericardial involvement is a rare but 
well known manifestation of FMF. Pericardial effusions 
in FMF usually regress with no permanent defect. 
Nonetheless, a study by Dabestani et al, demonstrated 
that there have been cases of pericardial tamponade and 
constrictive pericarditis secondary to FMF, as well as a 
higher risk of progression of FMF and amyloidosis in 
patients with pericardial involvement.4, 6 This highlights 
the importance of evaluating patients with FMF 
carefully and assessing for pericardial involvement. 
Long term follow up of such cases by both 
rheumatologists and cardiologists may help prevent the 
occurrence of complications. 
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Corinthia Group Prize in Paediatrics, 2015 
The Corinthia Group Prize in Paediatrics for 2015 was 
awarded to Dr Luke Saliba, who obtained the highest 
aggregate mark over the combined examinations in 
Paediatrics in the fourth and final year of the 
undergraduate course.  Whilst offering our 
congratulations to Dr Saliba, we would also like to 
congratulate all those who performed admirably during 
the undergraduate course in Paediatrics. In the 
accompanying photograph, Dr Saliba is seen receiving a 
cheque for €233 from Professor Simon Attard Montalto, 
Head of Paediatrics, in the Boardroom of Medical School. 
Finally, the Academic Department of Paediatrics and 
Medical School remain indebted and are extremely 
grateful to the Corinthia Group for their ongoing 
support. 
Professor Simon Attard Montalto 
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